Enhancing tumour binding avidity to potentiate cancer immunotherapy

Enhancing tumour binding avidity to potentiate cancer immunotherapy

Monday, March 29, 2021 3:40 PM to 4:00 PM · 20 min. (Africa/Abidjan)

Immunotherapy

Cell & gene therapy

Presentation

Information

Mark Lowdell, CSO, InMune Bio, Professor, UCL

LUMICKS LUMICKS creates instruments for dynamic single-molecule and cell avidity analysis. Our latest instrument, the z-Movi® Cell Avidity Analyzer, enables the measurement and selection of immune cells based on their interactions with cancer cells, providing a new parameter for experimentally evaluating immune cell functionality and activation. With this technology, scientists can measure cell avidity and obtain predictive, reproducible, and high-throughput results to compare several types of immunotherapeutic strategies, including CAR T cells, TCR T cells, bispecific antibodies, and NK cells.

Log in

See all the content and easy-to-use features by logging in or registering!